It has been reported that compared to controls, the protein level of VGLUT1 is decreased in the prefrontal cortex (PFC) of PD patients, revealing that VGLUT1 exerts the significant effects on glutamatergic damage in patients with PD (Kashani et al., 2007). Here, SLC17A7 is linked to Parkinson disease.